Elanco CEO granted 113 deferred stock units

Elanco Animal Health’s president and CEO Jeffrey N. Simmons reported an acquisition of derivative equity compensation.

Rhea-AI Filing Summary

Elanco Animal Health’s president and CEO Jeffrey N. Simmons reported an acquisition of derivative equity compensation. On January 23, 2026, he received 113.4934 deferred stock units at a reference price of $24.4 per unit, increasing his holdings to 18,959.0151 deferred stock units.

Each deferred stock unit gives the right to receive either one share of Elanco common stock or the cash equivalent. These units will settle in cash or shares after his employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.

Insider Trade Summary

Grant/Award: 113.4934 shares

Grant/Award 1 txn

Insider Simmons Jeffrey N

Role PRESIDENT, CEO AND DIRECTOR

Type	Security	Shares	Price	Value
Grant/Award	Deferred Stock Units	113.4934	$24.40	$3K

Holdings After Transaction: Deferred Stock Units — 18,959.0151 contracts (Direct)

Footnotes (2)

1. F1. Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.
2. F2. Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ELAN CEO Jeffrey N. Simmons report on January 23, 2026?

Jeffrey N. Simmons reported receiving 113.4934 deferred stock units on January 23, 2026. These units are a form of equity-based compensation tied to Elanco common stock or its cash equivalent under the company’s Executive Deferral and Stock Match Plan.

How many deferred stock units does ELAN CEO Jeffrey N. Simmons hold after this Form 4 filing?

After the reported transaction, Jeffrey N. Simmons beneficially owns 18,959.0151 deferred stock units. These units represent future rights to Elanco common stock or cash and form part of his long-term compensation and deferral arrangements with the company.

What are deferred stock units reported in the ELAN Form 4 for Jeffrey N. Simmons?

Deferred stock units are rights to receive one share of Elanco common stock or the cash equivalent. In this filing, they are granted under the Executive Deferral and Stock Match Plan, settling after employment ends or in a specified future year chosen under the plan.

At what price were the ELAN deferred stock units granted to Jeffrey N. Simmons?

The 113.4934 deferred stock units were reported with a reference price of $24.4 per unit. This price is used to value the derivative award in the filing and does not necessarily represent an immediate cash payment or traditional open-market share purchase.

Does the ELAN Form 4 indicate if Jeffrey N. Simmons’ deferred stock units are held directly or indirectly?

The filing shows the deferred stock units as held directly, marked with ownership form “D.” There is no notation of indirect ownership or related entities, so the award is attributed to Simmons personally under Elanco’s Executive Deferral and Stock Match Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/27/2026 - 04:28 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simmons Jeffrey N

(Last) (First) (Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS IN 46221

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT, CEO AND DIRECTOR

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Stock Units	(1)	01/23/2026		A		113.4934		(2)	(2)	Common Stock	113.4934	$24.4	18,959.0151	D

Explanation of Responses:

1. Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.

2. Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

	/s/ Amy C. Seidel, as Attorney-in-Fact for Jeffrey N. Simmons	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.